163 related articles for article (PubMed ID: 18793033)
1. Costs and effects of secondary prevention with perindopril in stable coronary heart disease in Poland: an analysis of the EUROPA study including 1251 Polish patients.
Redekop WK; Orlewska E; Maciejewski P; Rutten FF; Niessen LW
Pharmacoeconomics; 2008; 26(10):861-77. PubMed ID: 18793033
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study.
Briggs A; Mihaylova B; Sculpher M; Hall A; Wolstenholme J; Simoons M; Deckers J; Ferrari R; Remme WJ; Bertrand M; Fox K;
Heart; 2007 Sep; 93(9):1081-6. PubMed ID: 17135223
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).
Fox KM;
Lancet; 2003 Sep; 362(9386):782-8. PubMed ID: 13678872
[TBL] [Abstract][Full Text] [Related]
4. Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function.
Bertrand ME; Remme WJ; Fox KM; Ferrari R; Simoons ML;
Int J Cardiol; 2007 Sep; 121(1):57-61. PubMed ID: 17270296
[TBL] [Abstract][Full Text] [Related]
5. The EUROPA trial: design, baseline demography and status of the substudies.
Gomma AH; Fox KM
Cardiovasc Drugs Ther; 2001 Mar; 15(2):169-79. PubMed ID: 11669411
[TBL] [Abstract][Full Text] [Related]
6. Individualized Angiotensin-Converting Enzyme (ACE)-Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model.
Oemrawsingh RM; Akkerhuis KM; Van Vark LC; Redekop WK; Rudez G; Remme WJ; Bertrand ME; Fox KM; Ferrari R; Danser AH; de Maat M; Simoons ML; Brugts JJ; Boersma E;
J Am Heart Assoc; 2016 Mar; 5(3):e002688. PubMed ID: 27021566
[TBL] [Abstract][Full Text] [Related]
7. The EUROPA trial.
Brophy JM
Lancet; 2003 Dec; 362(9399):1936; author reply 1936-7. PubMed ID: 14667759
[No Abstract] [Full Text] [Related]
8. Perindopril and β-blocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: A EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysis.
Bertrand ME; Ferrari R; Remme WJ; Simoons ML; Fox KM
Am Heart J; 2015 Dec; 170(6):1092-8. PubMed ID: 26678630
[TBL] [Abstract][Full Text] [Related]
9. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT.
Ceconi C; Fox KM; Remme WJ; Simoons ML; Bertrand M; Parrinello G; Kluft C; Blann A; Cokkinos D; Ferrari R; ;
Cardiovasc Res; 2007 Jan; 73(1):237-46. PubMed ID: 17140552
[TBL] [Abstract][Full Text] [Related]
10. An economic evaluation of a perindopril-based blood pressure lowering regimen for patients who have suffered a cerebrovascular event.
Tavakoli M; Pumford N; Woodward M; Doney A; Chalmers J; MacMahon S; Macwalter R
Eur J Health Econ; 2009 Feb; 10(1):111-9. PubMed ID: 18446392
[TBL] [Abstract][Full Text] [Related]
11. [Clinical study of the month. The EUROPA study: cardiovascular protection with perindopril in patients with stable coronary heart disease].
Scheen AJ; Legrand V
Rev Med Liege; 2003 Nov; 58(11):713-6. PubMed ID: 14748202
[TBL] [Abstract][Full Text] [Related]
12. EUROPA: has anything new been learned with angiotensin-converting enzyme inhibitors?
Sica DA
J Clin Hypertens (Greenwich); 2004 Feb; 6(2):91-5. PubMed ID: 14872148
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin-converting enzyme inhibition with perindopril in patients with prior myocardial infarction and/or revascularization: a subgroup analysis of the EUROPA trial.
Bertrand ME; Fox KM; Remme WJ; Ferrari R; Simoons ML
Arch Cardiovasc Dis; 2009 Feb; 102(2):89-96. PubMed ID: 19303575
[TBL] [Abstract][Full Text] [Related]
14. The European trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA).
Fox KM; Henderson JR; Bertrand ME; Ferrari R; Remme WJ; Simoons ML
Eur Heart J; 1998 Sep; 19 Suppl J():J52-5. PubMed ID: 9796841
[TBL] [Abstract][Full Text] [Related]
15. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy.
Daly CA; Fox KM; Remme WJ; Bertrand ME; Ferrari R; Simoons ML;
Eur Heart J; 2005 Jul; 26(14):1369-78. PubMed ID: 15860521
[TBL] [Abstract][Full Text] [Related]
16. PERindopril-Function of the Endothelium in Coronary Artery Disease Trial: the PERFECT study--sub study of EUROPA: rationale and design.
Bots ML; Remme WJ; Lüscher TF; Grobbee DE;
Cardiovasc Drugs Ther; 2002 May; 16(3):227-36. PubMed ID: 12374901
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of ramipril in patients at high risk for cardiovascular events : economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the Statutory Health Insurance perspective.
Schädlich PK; Brecht JG; Rangoonwala B; Huppertz E
Pharmacoeconomics; 2004; 22(15):955-73. PubMed ID: 15449961
[TBL] [Abstract][Full Text] [Related]
18. Blocking the renin-angiotensin-aldosterone system or lowering the blood pressure: does EUROPA help?
Mackay JA
J Renin Angiotensin Aldosterone Syst; 2003 Dec; 4(4):205-6. PubMed ID: 14689366
[TBL] [Abstract][Full Text] [Related]
19. The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trial.
Brugts JJ; Boersma E; Chonchol M; Deckers JW; Bertrand M; Remme WJ; Ferrari R; Fox K; Simoons ML;
J Am Coll Cardiol; 2007 Nov; 50(22):2148-55. PubMed ID: 18036453
[TBL] [Abstract][Full Text] [Related]
20. Direct healthcare costs and cost-effectiveness of acute coronary syndrome secondary prevention with ticagrelor compared to clopidogrel: economic evaluation from the public payer's perspective in Poland based on the PLATO trial results.
Pawęska J; Macioch T; Perkowski P; Budaj A; Niewada M
Kardiol Pol; 2014; 72(9):823-30. PubMed ID: 24846362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]